Crossover Health

crossoverhealth.com

Crossover Health is driving the next-generation, employer-led health care movement, fundamentally changing the way care is practiced, delivered, and experienced. We partner with health activist employers who understand the value of growing their human capital, delivering a solution that meets their biggest obstacles – cost, access and engagement. Within our Primary Care Platform, our health centers serve as the hub to seamlessly integrate behavioral health, physical medicine, health coaching, as well as care navigation services, delivering an unrivaled patient experience. Utilizing our membership and tech-enabled model, employees are engaging in their health with unprecedented outcomes— we not only lower your total spend, but deliver unmatched NPS, Engagement and Patient Satisfaction scores allowing you to nurture your most important asset – your human capital.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

IMI RELEASES TAMPER EVIDENT CAPS WITH DOSEID CERTIFIED RFID

International Medical Industries, Inc. | February 28, 2022

news image

IMI bolsters expertise in secure drug delivery products with the release of new Prep-Lock Tamper Evident Cap for ENFit® and Oral Syringes with incorporated Radio Frequency Identification (RFID) technology. IMI's Prep-Lock line of Tamper Evident Products helps ensure medication safety from pharmacy to patient. The DoseID certified RFID Technology presents an opportunity to augment the proven benefits of tamper-evident products. "RFID technology represents the fut...

Read More

MARINUS PHARMACEUTICALS EARNS RARE PEDIATRIC DISEASE DESIGNATION FROM FDA FOR GANAXOLONE TREATING CDKL5 DEFICIENCY DISORDER (CDD)

Marinus Pharmaceuticals | July 31, 2020

news image

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the company’s product candidate ganaxolone for the treatment of CDKL5 deficiency disorder (CDD), a rare refractory form of pediatric epilepsy. “We are pleased that ganaxolone has received Rare Pediatric Dis...

Read More

Business Insights

KYOWA KIRIN EXPANDS LICENSE AGREEMENT WITH SYNAFFIX AND TAKES EXCLUSIVE TARGET RIGHTS BASED ON LATEST POSITIVE ADC DATA

Synaffix | July 01, 2022

news image

Synaffix B.V. a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates with best-in-class therapeutic index, today announces that Kyowa Kirin Co., Ltd.a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies, has expanded the license agreement with Synaffix by adding a third ADC target to its research evaluation and development effor...

Read More

PDC LINE PHARMA RAISES €20 MILLION IN SERIES B FINANCING ROUND

Business Wire | January 22, 2020

news image

PDC line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, announces today the completion of its Series B round of financing. The company has raised a total of €20 million ($22.2M). Two and a half years after its last round of fundraising in July 2017, PDC*line Pharma has attracted new investors, securing a further capital increase of €13.9M ($15.5M). In addition, the company will receive €6.1M ($6.8M) in loa...

Read More
news image

Pharmacy Market

IMI RELEASES TAMPER EVIDENT CAPS WITH DOSEID CERTIFIED RFID

International Medical Industries, Inc. | February 28, 2022

IMI bolsters expertise in secure drug delivery products with the release of new Prep-Lock Tamper Evident Cap for ENFit® and Oral Syringes with incorporated Radio Frequency Identification (RFID) technology. IMI's Prep-Lock line of Tamper Evident Products helps ensure medication safety from pharmacy to patient. The DoseID certified RFID Technology presents an opportunity to augment the proven benefits of tamper-evident products. "RFID technology represents the fut...

Read More
news image

MARINUS PHARMACEUTICALS EARNS RARE PEDIATRIC DISEASE DESIGNATION FROM FDA FOR GANAXOLONE TREATING CDKL5 DEFICIENCY DISORDER (CDD)

Marinus Pharmaceuticals | July 31, 2020

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the company’s product candidate ganaxolone for the treatment of CDKL5 deficiency disorder (CDD), a rare refractory form of pediatric epilepsy. “We are pleased that ganaxolone has received Rare Pediatric Dis...

Read More
news image

Business Insights

KYOWA KIRIN EXPANDS LICENSE AGREEMENT WITH SYNAFFIX AND TAKES EXCLUSIVE TARGET RIGHTS BASED ON LATEST POSITIVE ADC DATA

Synaffix | July 01, 2022

Synaffix B.V. a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates with best-in-class therapeutic index, today announces that Kyowa Kirin Co., Ltd.a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies, has expanded the license agreement with Synaffix by adding a third ADC target to its research evaluation and development effor...

Read More
news image

PDC LINE PHARMA RAISES €20 MILLION IN SERIES B FINANCING ROUND

Business Wire | January 22, 2020

PDC line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, announces today the completion of its Series B round of financing. The company has raised a total of €20 million ($22.2M). Two and a half years after its last round of fundraising in July 2017, PDC*line Pharma has attracted new investors, securing a further capital increase of €13.9M ($15.5M). In addition, the company will receive €6.1M ($6.8M) in loa...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us